Katie Moynihan, M.B.,B.S.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Extracorporeal Membrane Oxygenation | 21 | 2024 | 1483 | 6.120 |
Why?
|
| Intensive Care Units, Pediatric | 12 | 2023 | 1024 | 3.020 |
Why?
|
| Terminal Care | 8 | 2024 | 1772 | 2.260 |
Why?
|
| Virus Diseases | 3 | 2020 | 724 | 1.220 |
Why?
|
| Delphi Technique | 3 | 2024 | 890 | 1.040 |
Why?
|
| Heart Diseases | 5 | 2024 | 2819 | 0.970 |
Why?
|
| Respiratory Insufficiency | 2 | 2023 | 1241 | 0.920 |
Why?
|
| Hemostatics | 2 | 2024 | 246 | 0.910 |
Why?
|
| Child | 40 | 2024 | 80969 | 0.860 |
Why?
|
| Ethics Consultation | 1 | 2024 | 59 | 0.860 |
Why?
|
| Hospitalization | 5 | 2023 | 10845 | 0.790 |
Why?
|
| Partial Thromboplastin Time | 2 | 2021 | 204 | 0.770 |
Why?
|
| Tranexamic Acid | 1 | 2024 | 174 | 0.770 |
Why?
|
| Prothrombin Time | 1 | 2021 | 117 | 0.760 |
Why?
|
| Healthcare Disparities | 4 | 2024 | 3421 | 0.740 |
Why?
|
| Hospital Mortality | 5 | 2024 | 5369 | 0.740 |
Why?
|
| Critical Care | 8 | 2023 | 2715 | 0.730 |
Why?
|
| Antifibrinolytic Agents | 1 | 2024 | 289 | 0.730 |
Why?
|
| Palliative Care | 7 | 2024 | 3644 | 0.710 |
Why?
|
| Respiratory Tract Infections | 2 | 2019 | 1014 | 0.680 |
Why?
|
| Oximetry | 1 | 2023 | 462 | 0.680 |
Why?
|
| Liver Failure, Acute | 1 | 2021 | 182 | 0.680 |
Why?
|
| Infant | 22 | 2024 | 36541 | 0.680 |
Why?
|
| Hemoptysis | 1 | 2021 | 152 | 0.670 |
Why?
|
| Thrombelastography | 1 | 2021 | 194 | 0.650 |
Why?
|
| Tracheostomy | 1 | 2023 | 430 | 0.650 |
Why?
|
| Decision Making | 3 | 2024 | 3952 | 0.640 |
Why?
|
| Pneumonia, Mycoplasma | 1 | 2018 | 50 | 0.620 |
Why?
|
| Intubation | 1 | 2019 | 140 | 0.610 |
Why?
|
| Referral and Consultation | 3 | 2023 | 3626 | 0.590 |
Why?
|
| Communication | 4 | 2024 | 3908 | 0.550 |
Why?
|
| Heparin | 3 | 2020 | 1636 | 0.540 |
Why?
|
| Viruses | 1 | 2020 | 373 | 0.530 |
Why?
|
| Blood Coagulation | 2 | 2021 | 1161 | 0.530 |
Why?
|
| Infant, Newborn | 17 | 2024 | 26394 | 0.530 |
Why?
|
| Blood Coagulation Tests | 1 | 2017 | 270 | 0.520 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 5375 | 0.490 |
Why?
|
| Transportation of Patients | 1 | 2016 | 177 | 0.480 |
Why?
|
| Critical Illness | 4 | 2024 | 2754 | 0.460 |
Why?
|
| Myocarditis | 1 | 2021 | 803 | 0.450 |
Why?
|
| Heart Defects, Congenital | 3 | 2020 | 4711 | 0.440 |
Why?
|
| Death | 3 | 2023 | 683 | 0.430 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2020 | 3683 | 0.430 |
Why?
|
| Cause of Death | 2 | 2021 | 3721 | 0.390 |
Why?
|
| Anticoagulants | 7 | 2024 | 4850 | 0.390 |
Why?
|
| Retrospective Studies | 19 | 2024 | 81892 | 0.390 |
Why?
|
| Australia | 3 | 2020 | 1265 | 0.380 |
Why?
|
| Oxygen | 1 | 2023 | 4273 | 0.380 |
Why?
|
| Humans | 55 | 2024 | 768887 | 0.370 |
Why?
|
| Family | 1 | 2022 | 3208 | 0.370 |
Why?
|
| Thrombosis | 2 | 2022 | 2956 | 0.360 |
Why?
|
| Child, Preschool | 13 | 2024 | 42684 | 0.350 |
Why?
|
| Maternal Welfare | 1 | 2010 | 113 | 0.350 |
Why?
|
| Registries | 2 | 2024 | 8384 | 0.340 |
Why?
|
| Intensive Care Units | 2 | 2023 | 3800 | 0.340 |
Why?
|
| Cross Infection | 1 | 2019 | 1425 | 0.330 |
Why?
|
| Physician-Patient Relations | 2 | 2024 | 3269 | 0.330 |
Why?
|
| Patient Transfer | 1 | 2016 | 792 | 0.310 |
Why?
|
| Length of Stay | 5 | 2024 | 6525 | 0.300 |
Why?
|
| Health Priorities | 1 | 2010 | 380 | 0.290 |
Why?
|
| New Zealand | 2 | 2019 | 360 | 0.280 |
Why?
|
| Child Welfare | 1 | 2010 | 523 | 0.270 |
Why?
|
| Melphalan | 2 | 1997 | 421 | 0.240 |
Why?
|
| Factor VIIa | 1 | 2024 | 103 | 0.220 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 15955 | 0.210 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 1997 | 618 | 0.200 |
Why?
|
| Heart Failure | 2 | 2023 | 11879 | 0.200 |
Why?
|
| Child Mortality | 2 | 2016 | 204 | 0.190 |
Why?
|
| Dissent and Disputes | 1 | 2022 | 150 | 0.180 |
Why?
|
| Technology | 1 | 2023 | 296 | 0.180 |
Why?
|
| Adolescent | 8 | 2024 | 89247 | 0.170 |
Why?
|
| Consensus | 3 | 2024 | 3214 | 0.170 |
Why?
|
| Social Responsibility | 1 | 2022 | 384 | 0.160 |
Why?
|
| Coronary Care Units | 1 | 2021 | 235 | 0.160 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2023 | 327 | 0.160 |
Why?
|
| Respiration, Artificial | 2 | 2023 | 2724 | 0.160 |
Why?
|
| Mycoplasma pneumoniae | 1 | 2018 | 43 | 0.160 |
Why?
|
| Hospital Charges | 1 | 2021 | 351 | 0.160 |
Why?
|
| Paternalism | 1 | 2018 | 49 | 0.160 |
Why?
|
| Fetal Diseases | 1 | 2023 | 916 | 0.150 |
Why?
|
| Femoral Artery | 1 | 2022 | 829 | 0.140 |
Why?
|
| Acetaminophen | 1 | 2021 | 556 | 0.140 |
Why?
|
| Blood Transfusion | 1 | 2024 | 1309 | 0.140 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 26384 | 0.140 |
Why?
|
| Travel | 1 | 2023 | 805 | 0.140 |
Why?
|
| Catheterization | 1 | 2022 | 1431 | 0.140 |
Why?
|
| Withholding Treatment | 1 | 2021 | 620 | 0.130 |
Why?
|
| Amino Acid Oxidoreductases | 1 | 1997 | 149 | 0.130 |
Why?
|
| Aphidicolin | 1 | 1996 | 37 | 0.130 |
Why?
|
| Zalcitabine | 1 | 1996 | 43 | 0.130 |
Why?
|
| DNA Polymerase I | 1 | 1996 | 44 | 0.130 |
Why?
|
| Male | 14 | 2024 | 365249 | 0.130 |
Why?
|
| Health Services Accessibility | 2 | 2024 | 5520 | 0.130 |
Why?
|
| Female | 16 | 2024 | 397464 | 0.130 |
Why?
|
| DNA Polymerase II | 1 | 1996 | 104 | 0.120 |
Why?
|
| Tetralogy of Fallot | 1 | 2020 | 628 | 0.120 |
Why?
|
| Preoperative Period | 1 | 2017 | 565 | 0.120 |
Why?
|
| Community-Acquired Infections | 1 | 2018 | 473 | 0.120 |
Why?
|
| Recombinant Proteins | 1 | 2024 | 6512 | 0.120 |
Why?
|
| Hospitals, Pediatric | 1 | 2024 | 1876 | 0.120 |
Why?
|
| Anesthesia, General | 1 | 2021 | 1189 | 0.120 |
Why?
|
| Reference Values | 1 | 2021 | 4941 | 0.110 |
Why?
|
| Statistics, Nonparametric | 1 | 2019 | 2862 | 0.110 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 20244 | 0.110 |
Why?
|
| Chi-Square Distribution | 1 | 2019 | 3438 | 0.100 |
Why?
|
| Hemorrhage | 1 | 2024 | 3465 | 0.100 |
Why?
|
| Birth Weight | 1 | 2020 | 2108 | 0.100 |
Why?
|
| United States | 3 | 2024 | 73180 | 0.090 |
Why?
|
| Patient Discharge | 2 | 2021 | 3490 | 0.090 |
Why?
|
| Amino Acids | 1 | 1997 | 1716 | 0.090 |
Why?
|
| Postoperative Care | 1 | 2017 | 1481 | 0.090 |
Why?
|
| Health Personnel | 1 | 2023 | 3382 | 0.080 |
Why?
|
| Hospitals | 1 | 2023 | 3903 | 0.080 |
Why?
|
| Medicaid | 1 | 2023 | 2843 | 0.080 |
Why?
|
| Incidence | 2 | 2018 | 21545 | 0.080 |
Why?
|
| Patient Participation | 1 | 2018 | 1448 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2022 | 54950 | 0.070 |
Why?
|
| Cardiology | 1 | 2019 | 1701 | 0.070 |
Why?
|
| Comorbidity | 1 | 2022 | 10591 | 0.070 |
Why?
|
| Maternal Mortality | 1 | 2010 | 307 | 0.070 |
Why?
|
| Developing Countries | 1 | 2020 | 2906 | 0.070 |
Why?
|
| Age Factors | 2 | 2021 | 18454 | 0.070 |
Why?
|
| Parents | 1 | 2021 | 3597 | 0.070 |
Why?
|
| Heart | 1 | 2020 | 4448 | 0.070 |
Why?
|
| Survival Rate | 1 | 2021 | 12873 | 0.070 |
Why?
|
| Pain | 1 | 2021 | 5100 | 0.070 |
Why?
|
| Uganda | 1 | 2010 | 1354 | 0.060 |
Why?
|
| Risk Factors | 4 | 2023 | 74971 | 0.060 |
Why?
|
| Models, Biological | 1 | 2021 | 9499 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 1996 | 3724 | 0.060 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 15471 | 0.060 |
Why?
|
| Alabama | 1 | 2024 | 112 | 0.060 |
Why?
|
| Physicians | 1 | 2022 | 4607 | 0.060 |
Why?
|
| Prognosis | 2 | 2022 | 30044 | 0.060 |
Why?
|
| Pediatrics | 1 | 2019 | 3628 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 7460 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 12093 | 0.050 |
Why?
|
| Pandemics | 1 | 2023 | 8745 | 0.050 |
Why?
|
| Mice, Nude | 3 | 2000 | 3631 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2023 | 65485 | 0.050 |
Why?
|
| Glioma | 1 | 1997 | 3532 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 7472 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2021 | 24330 | 0.040 |
Why?
|
| Protamines | 1 | 2019 | 112 | 0.040 |
Why?
|
| Time Factors | 1 | 2021 | 40266 | 0.040 |
Why?
|
| Ventilators, Mechanical | 1 | 2021 | 292 | 0.040 |
Why?
|
| Health Policy | 1 | 2010 | 2700 | 0.040 |
Why?
|
| L-Amino Acid Oxidase | 1 | 1997 | 6 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 2 | 1997 | 6232 | 0.040 |
Why?
|
| Catheters | 1 | 2020 | 427 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2019 | 1629 | 0.030 |
Why?
|
| Carbon Dioxide | 1 | 2021 | 1149 | 0.030 |
Why?
|
| Camptothecin | 1 | 2000 | 600 | 0.030 |
Why?
|
| Carmustine | 1 | 1996 | 137 | 0.030 |
Why?
|
| Device Removal | 1 | 2021 | 643 | 0.030 |
Why?
|
| Infant, Low Birth Weight | 1 | 2020 | 868 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 1997 | 9213 | 0.030 |
Why?
|
| Guanine | 1 | 1996 | 280 | 0.030 |
Why?
|
| Aftercare | 1 | 2020 | 921 | 0.030 |
Why?
|
| India | 1 | 2020 | 2325 | 0.030 |
Why?
|
| Infant, Premature | 1 | 2023 | 2121 | 0.030 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2020 | 862 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2016 | 41800 | 0.030 |
Why?
|
| Rhabdomyosarcoma | 1 | 1996 | 358 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 1996 | 2018 | 0.020 |
Why?
|
| Drug Synergism | 1 | 1996 | 1762 | 0.020 |
Why?
|
| Blood-Brain Barrier | 1 | 1997 | 1036 | 0.020 |
Why?
|
| Adult | 2 | 2022 | 223818 | 0.020 |
Why?
|
| Sarcoma | 1 | 2000 | 1806 | 0.020 |
Why?
|
| Patient Selection | 1 | 2021 | 4265 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2024 | 3463 | 0.020 |
Why?
|
| Antibodies | 1 | 1997 | 2422 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 1997 | 2395 | 0.020 |
Why?
|
| Premature Birth | 1 | 2020 | 1814 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 10778 | 0.020 |
Why?
|
| Antineoplastic Agents | 2 | 2000 | 13699 | 0.020 |
Why?
|
| Mice | 3 | 2000 | 82074 | 0.010 |
Why?
|
| KB Cells | 1 | 2000 | 13 | 0.010 |
Why?
|
| Topotecan | 1 | 2000 | 131 | 0.010 |
Why?
|
| Carbon Radioisotopes | 1 | 2000 | 567 | 0.010 |
Why?
|
| Liposomes | 1 | 2000 | 792 | 0.010 |
Why?
|
| Animals | 3 | 2000 | 169408 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2000 | 2299 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2000 | 1645 | 0.010 |
Why?
|
| Drug Carriers | 1 | 2000 | 710 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2000 | 3621 | 0.010 |
Why?
|